China ’s first Smeglugin peptide biological generic drug declaration is listed on the

The first Simeogupeptide biological generic drug that appeared in China appeared in China.It is still unreasonable, hoping that the state will continue to support and protect innovation.

Comprehensive Shanghai Securities Journal and First Financial Report, the China Pharmaceutical Supervision Bureau Drug Review Center (CDE) website on Wednesday (April 3) shows that the biological similar pharmaceutical division of Jiuyuan Gene isApplication for the launch of the injection is also accepted, which is also the first Simeoguptide biochetic drug in China, which is the first to apply for the listing. The drug is used to control type 2 diabetes.

Jiuyuan Gene is all known as Hangzhou Jiuyuan Gene Engineering Co., Ltd., founded in 1993.In January of this year, Jiuyuan Gene had submitted the first public sales (IPO) application to the Hong Kong Stock Exchange and received acceptance.

According to the company's prospectus, the company has the experience of developing metabolic disease drugs for nearly 18 years.Pulfide biosimination medicine.This time, the Sammeglugin peptide biological injection similar drug was listed. The product obtained a clinical implied permission in 2021 and completed the clinical phase 3 study in 2023.In addition, Jiuyuan Gene is still developing oral Somera peptide biological drugs for the treatment of obesity and overweight. It is currently in the preclinical research stage.

Smeglugin is currently the best-selling GLP-1 drug. In addition to the efficacy of hypoglycemic, this drug is increasingly used for weight loss.

Somera Peptide Original Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Nord's current Smeglugin peptide in China is used in type 2 diabetes therapy drugs for "Nova Thai".Hetai's sales in China increased more than doubled last year, reaching 4.8 billion Dan Ying Crown (approximately S $ 940 million), accounting for about 5%of the US $ 14 billion in the world.The company's patent protection period was 2026.

Novo and Nord responded to the media inquiry that the patent patent of Smegugu peptide will expire in 2026.The invalid case of the Patent Patent of the Smegugu Plan has no final conclusion and is still tried in the Supreme People's Court Intellectual Property Court.

Novo and Nord also said that he hopes that the country will continue to support and protect innovation, thereby motivating enterprises to innovate.